pbpk modeling approaches to assess risks associated with bioequivalence in drug development
Published 3 years ago • 547 plays • Length 59:49Download video MP4
Download video MP3
Similar videos
-
49:40
pbpk modeling and simulation: bridging the “bottom up” and “top-down” approaches
-
55:39
a best practice framework for applying pbpk modeling to pediatric drug development
-
58:36
pbpk for the pill an approach to assess the risk benefit of drugs
-
49:08
achieving virtual bioequivalence with pbpk in lieu of clinical studies
-
3:39
common myths about pbpk modeling and simulation- busted!
-
1:21:18
operational risk
-
9:40
biorisk management: the 'amp' model: cc-by
-
23:02
introduction to baseline risk assessment using the pepmelf methodology
-
1:02:16
leveraging dermal pbpk modeling and simulation approaches
-
50:49
pbpk modeling to predict pharmacokinetics in hepatic impairment
-
50:49
pbpk modeling and simulation for regulatory decision making: impact on us prescribing information
-
59:23
first-in-human (fih) faster: the power of physiologically based pharmacokinetic (pbpk) modeling
-
1:01:14
pbpk modeling & simulation to support asciminib nda submission and inform drug product label
-
40:57
precision dosing using pbpk modeling
-
59:17
applications of pbpk modelling for regulatory submissions: case studies
-
27:50
pbpk based approach towards risk assessment
-
1:52
pbpk modeling supports approval of breakthrough cancer drug
-
55:43
pbpk modelling to predict drug-biologic interactions with cytokine modulators
-
1:02:46
solving a mystery using pbpk: how drug-excipient complexes can confound a metabolic ddi result
-
1:06:27
the importance of pbpk model validation and reproducibility in obstetric pharmacology
-
13:20
developing compound files for pbpk modeling in the simcyp simulator